ArticleIndian journal of clinical biochemistry : IJCB2025
Role of Cell-free DNA as a Non-Invasive Biomarker in the Detection of Head and Neck Squamous Cell Carcinoma.
Article in Indian journal of clinical biochemistry : IJCB, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Saliva vs Plasma in Liquid Biopsy Sampling for Head and Neck Cancer: A Comparative Study.Clinical chemistry · 2026Article
- Emerging Diagnostic Strategies for Oral Cancer and Oral Potentially Malignant Disorders: A PRISMA-Guided Scoping Review.Diagnostics (Basel, Switzerland) · 2026Review
- Circulating Cell-Free DNA Concentration as a Biomarker in Head and Neck Cancer.Oral diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Head and neck squamous cell carcinomas (HNSCC) are the sixth leading cancer by incidence worldwide. Small fragments of cell-free DNA (cfDNA) are present in the circulation with elevated levels in cancer patients. Their concentration correlates with tumor size, disease stage, and metastatic burden. Our present study aims to determine the utility of cfDNA as an early screening and diagnostic tool in patients with HNSCC. A cross-sectional study was conducted. The cohort included 35 biopsy-confirmed cases of HNSCC and 35 age and sex-matched healthy controls. cfDNA was extracted using 3 ml plasma with QIAamp Circulating Nucleic acid kit and quantified using UV Spectrophotometry. Mean levels of plasma cfDNA were elevated in patients with HNSCC compared to controls (Mean of 17.10 ng/μl and 15.26 ng/μl, respectively), although the difference was not significant (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.